CN103462954B - Application of Nardoaristolones A in preparation of medicaments for treating skin cancer - Google Patents
Application of Nardoaristolones A in preparation of medicaments for treating skin cancer Download PDFInfo
- Publication number
- CN103462954B CN103462954B CN201310405513.6A CN201310405513A CN103462954B CN 103462954 B CN103462954 B CN 103462954B CN 201310405513 A CN201310405513 A CN 201310405513A CN 103462954 B CN103462954 B CN 103462954B
- Authority
- CN
- China
- Prior art keywords
- nardoaristolones
- medicaments
- application
- preparation
- skin cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930191730 nardoaristolone Natural products 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 201000000849 skin cancer Diseases 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 208000000453 Skin Neoplasms Diseases 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 15
- 201000008261 skin carcinoma Diseases 0.000 claims description 11
- 230000012010 growth Effects 0.000 abstract description 7
- 102100027833 14-3-3 protein sigma Human genes 0.000 abstract description 6
- 101100107350 Homo sapiens SFN gene Proteins 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000790228 Nardostachys jatamansi Species 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of Nardoaristolones A in preparation of medicaments for treating skin canner, and belongs to the technical field of new application of the medicaments. In vitro MTT (3-4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) anti-tumor activity evaluation discovers that Nardoaristolones A also has a remarkable effect on inhibiting the growth of human skin cancer cell strains A431, HME1, A375 and SK23, so that Nardoaristolones A can be used for preparing the medicaments for resisting the skin caner, and has a good development and application prospect, high inhibiting activity, prominent substantive features and significant progress.
Description
Technical field
The present invention relates to the novelty teabag of compound N ardoaristolones A, particularly relate to the application of Nardoaristolones A in preparation treatment skin carcinoma medicine.
Background technology
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound N ardoaristolones A that the present invention relates to is one and delivers (Ming-Li Liu in 2013, Ying-Hui Duan, Yun-Long Hou, et al.Nardoaristolones A and B, Two Terpenoids with Unusual Skeletons from Nardostachys chinensis Batal.Organic Letters, 2013, noval chemical compound 15(5): 1000 – 1003.), this compound has brand-new framework types, current purposes only has protective effect (Ming-Li Liu to the myocardial damage of hydrogen peroxide induction, Ying-Hui Duan, Yun-Long Hou, et al.Nardoaristolones A and B, Two Terpenoids with Unusual Skeletons from Nardostachys chinensis Batal.Organic Letters, 2013, 15(5): 1000 – 1003.), the purposes of the Nardoaristolones A that the present invention relates in preparation treatment skin carcinoma medicine belongs to first public, belong to brand-new structure type.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report of anti-skin carcinoma activity according in existing Nardoaristolones A research, provide the application of Nardoaristolones A in the anti-skin carcinoma medicine of preparation.
Described compound N ardoaristolones A, structure is as shown in formula I:
The present invention is found by external MTT antineoplastic activity evaluation, Nardoaristolones A also has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23, suppresses the IC50 value of this 4 strain Growth of Cells to be respectively 2.75 ± 0.36 μMs, 1.78 ± 0.42 μMs, 1.65 ± 0.34 μMs and 1.87 ± 0.54 μMs.Therefore, Nardoaristolones A for the preparation of anti-skin carcinoma medicine, can have good development prospect.
The purposes of the Nardoaristolones A that the present invention relates in preparation treatment skin carcinoma medicine is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for skin cancer cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for skin carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound N ardoaristolones A involved in the present invention is see document (Ming-Li Liu, Ying-Hui Duan, Yun-Long Hou, et al.Nardoaristolones A and B, Two Terpenoids with Unusual Skeletons from Nardostachys chinensis Batal.Organic Letters, 2013,15(5): 1000 – 1003.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound N ardoaristolones A tablet involved in the present invention:
Get 5 g of compound Nardoaristolones A, add 195 grams, dextrin, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compound N ardoaristolones A capsule involved in the present invention:
Get 5 g of compound Nardoaristolones A, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Nardoaristolones A to the growth inhibited effect of application on human skin JEG-3
1. method: the cell being in growth logarithmic (log) phase: application on human skin JEG-3 A431, HME1, A375 and SK23(buy from Chinese Academy of Sciences's cell bank) with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the Nardoaristolones A of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD drug treating/Δ OD blank × 100.
2. result: the growth of Nardoaristolones A to application on human skin JEG-3 A431, HME1, A375 and SK23 has significant inhibitory action.This compound suppresses application on human skin JEG-3 A431, the IC50 value of HME1, A375 and SK23 growth is respectively 2.75 ± 0.36 μMs, 1.78 ± 0.42 μMs, 1.65 ± 0.34 μMs and 1.87 ± 0.54 μMs.
Shown by above-described embodiment, the growth of Nardoaristolones A of the present invention to application on human skin JEG-3 A431, HME1, A375 and SK23 has good inhibitory action.Prove thus, it is active that Nardoaristolones A of the present invention has anti-skin carcinoma, can for the preparation of anti-skin carcinoma medicine.
Claims (1)
- The application of 1.Nardoaristolones A in preparation treatment skin carcinoma medicine, described compound N ardoaristolones A structure is as shown in formula I:Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310405513.6A CN103462954B (en) | 2013-09-06 | 2013-09-06 | Application of Nardoaristolones A in preparation of medicaments for treating skin cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310405513.6A CN103462954B (en) | 2013-09-06 | 2013-09-06 | Application of Nardoaristolones A in preparation of medicaments for treating skin cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103462954A CN103462954A (en) | 2013-12-25 |
| CN103462954B true CN103462954B (en) | 2015-05-20 |
Family
ID=49788152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310405513.6A Active CN103462954B (en) | 2013-09-06 | 2013-09-06 | Application of Nardoaristolones A in preparation of medicaments for treating skin cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103462954B (en) |
-
2013
- 2013-09-06 CN CN201310405513.6A patent/CN103462954B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Nardoaristolones A and B, Two Terpenoids with Unusual Skeletons from Nardostachys chinensis Batal;Ming-Li Liu, et al.;《ORGANIC LETTERS》;20130208;第15卷(第 5期);1000-1003 * |
| 甘松属植物化学成分与药理作用;万新 等;《国外医药•植物药分册》;20071231;第22卷(第1期);1-6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103462954A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250250A (en) | Application of Nootkatone in preparation of medicine for treating nasopharyngeal carcinoma | |
| CN103462954B (en) | Application of Nardoaristolones A in preparation of medicaments for treating skin cancer | |
| CN103405407B (en) | Application of compound in preparation of medicines for treating pancreatic cancer | |
| CN103638008B (en) | The application of Artoxanthochromane in treatment skin carcinoma medicine | |
| CN102872086B (en) | The application of Houttuynoid A in treatment skin carcinoma medicine | |
| CN103462953B (en) | Application of Nardoaristolones A in preparation of medicaments for treating tongue cancer | |
| CN103462955B (en) | Application of Nardoaristolones A in preparation of medicaments for treating stomach cancer | |
| CN103462952B (en) | Application of Nardoaristolones A in preparation of medicaments for treating ovarian cancer | |
| CN105456243A (en) | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer | |
| CN105267193A (en) | Application of Periconianone B to preparation of medicine for treating ovarian cancer | |
| CN105267221A (en) | Application of Norzoanthamine in preparation of drugs for treating prostate cancer | |
| CN103405406B (en) | The application of a kind of compound in preparation treatment endometrial cancer drug | |
| CN103405420B (en) | The application of Chukrasone B in preparation treatment medicine for nasopharyngeal | |
| CN103405447B (en) | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal | |
| CN103446088B (en) | The application of Incarviatone A in preparation treatment skin carcinoma medicine | |
| CN103405421B (en) | Application of Chukrasone B in medicine for treating cervical cancer | |
| CN103405451B (en) | The application of Chukrasone A in preparation treatment tongue cancer drug | |
| CN103446128B (en) | The application of Lycojaponicumin B in preparation treatment skin carcinoma medicine | |
| CN103405444B (en) | The application of Chukrasone A in preparation treatment bladder cancer medicine | |
| CN103463069B (en) | The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal | |
| CN103479632B (en) | The application of Lycojaponicumin B in preparation treatment cervical cancer medicine | |
| CN103446089B (en) | The application of Incarviatone A in preparation treatment medicine for nasopharyngeal | |
| CN103463044B (en) | The application of Lycojaponicumin A in preparation treatment skin carcinoma medicine | |
| CN103446147B (en) | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine | |
| CN103638016B (en) | Application of Manzamenone O in rectal cancer treatment drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENGZHOU LIMEI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YAN JIANDI Effective date: 20150318 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 312365 SHAOXING, ZHEJIANG PROVINCE TO: 312464 SHAOXING, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150318 Address after: 312464, Shaoxing, Zhejiang Province, Shengzhou Town, Taoyuan Road, No. 207, third floor Applicant after: SHENGZHOU LINMEI BIOTECHNOLOGY CO., LTD. Address before: 312365 Zhejiang province Shaoxing Sanyou Village Bridge Songxia town north of Shangyu City No. 96 Applicant before: Yan Jiandi |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 223100 Renmin Road, Hongze County, Jiangsu, Huaian Patentee after: SHENGZHOU LINMEI BIOTECHNOLOGY CO., LTD. Address before: 312464, Shaoxing, Zhejiang Province, Shengzhou Town, Taoyuan Road, No. 207, third floor Patentee before: SHENGZHOU LINMEI BIOTECHNOLOGY CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Kuifeng Inventor before: Yan Jiandi |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160411 Address after: Jenai road Loufeng Town District of Suzhou City, Jiangsu province Pingjiang 215123 150 No. second teaching building Patentee after: SUZHOU GENHOUSE PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. Address before: 223100 Renmin Road, Hongze County, Jiangsu, Huaian Patentee before: SHENGZHOU LINMEI BIOTECHNOLOGY CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 215123 Suzhou Industrial Park, Jiangsu Province, if the water No. 388 D505, D507 room Patentee after: Qin Hao Pharmaceutical (Suzhou) Co., Ltd. Address before: Jenai road Loufeng Town District of Suzhou City, Jiangsu province Pingjiang 215123 150 No. second teaching building Patentee before: SUZHOU GENHOUSE PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220104 Address after: 201203 No. 27, Lane 1000, zhangheng Road, pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: Qinyan Haosheng Pharmaceutical (Shanghai) Co.,Ltd. Address before: 215123 rooms D505 and d507, 388 Ruoshui Road, Suzhou Industrial Park, Jiangsu Province Patentee before: SUZHOU GENHOUSE PHARMACEUTICAL Co.,Ltd. |